3 Reasons to Sell VTRS and 1 Stock to Buy Instead [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Is now the time to buy Viatris, or should you be careful about including it in your portfolio? Check out our in-depth research report to see what our analysts have to say, it's free We're happy investors have made money, but we're swiping left on Viatris for now. Here are three reasons why VTRS doesn't excite us and a stock we'd rather own. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Regrettably, Viatris's sales grew at a mediocre 4.2% compounded annual growth rate over the last five years. This fell short of our benchmark for the healthcare sector. We track the long-term change in earnings per share (EPS) because it highlights whether a company's growth is profitable. Sadly for Viatris, its EPS declined by 1
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Davis Opportunity Fund Annual Review 2026 [Seeking Alpha]Seeking Alpha
- Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch [Yahoo! Finance]Yahoo! Finance
- Is Viatris (VTRS) Pricing Reflect Its Recent Multi-Year Share Price Recovery [Yahoo! Finance]Yahoo! Finance
- Viatris Earnings Preview: What to Expect [Yahoo! Finance]Yahoo! Finance
- Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 11/6/25 - Beat
VTRS
Sec Filings
- 1/2/26 - Form 4
- 12/8/25 - Form 8-K
- 12/5/25 - Form 8-K
- VTRS's page on the SEC website